Peginterferon-α combined with capecitabine inhibits tumor growth in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential

沈早卓,周俭,肖永胜,樊嘉,薛琼,高东梅,汤钊猷

DOI: https://doi.org/10.3760/j.issn:1001-9030.2006.03.007

2006-01-01

Abstract:To investigate the therapeutic and side effects of Peginterferon-α combined with capecitabine on tumor growth in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Methods Thirty nude mice were randomly divided into 4 groups and were administered respectively with controls, Peginterferon-α, capecitabine, combination of Peginterferon-α and capecitabine respectively. The weight of nude mice was measured once a week. The tumor size was calculated after the mice were killed. The blood were collected for the routine analysis of liver and renal functions. Results In the control, Peginterferon-α, capecitabine and combination groups, tumor volume was (2 275± 1 337), (336± 220), (889± 614) and (26± 56) mm~3 respectively. After the intervention, the tumor volume was significantly smaller than that in the control. The tumor shrinkage was most significantly observed in the group of Peginterferon-α combined with capecitabine (P<0.01). The combination of Peginterferon-α and capecitabine showed no synergistic toxicity in terms of weight loss or damage of liver and renal functions. Conclusion Peginterferon-αcombined with capecitabine may significantly inhibit the liver tumor growth in LCI-D20 nude mice with no significant toxicity and side effects.